KR100814214B1 - Immuno-stimulative composite comprising extract from bamboo sap - Google Patents

Immuno-stimulative composite comprising extract from bamboo sap Download PDF

Info

Publication number
KR100814214B1
KR100814214B1 KR1020060098710A KR20060098710A KR100814214B1 KR 100814214 B1 KR100814214 B1 KR 100814214B1 KR 1020060098710 A KR1020060098710 A KR 1020060098710A KR 20060098710 A KR20060098710 A KR 20060098710A KR 100814214 B1 KR100814214 B1 KR 100814214B1
Authority
KR
South Korea
Prior art keywords
sap
bamboo
extract
bamboo sap
composition
Prior art date
Application number
KR1020060098710A
Other languages
Korean (ko)
Inventor
조숙현
최철웅
최용조
허재영
노치웅
송근우
Original Assignee
경상남도
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경상남도 filed Critical 경상남도
Priority to KR1020060098710A priority Critical patent/KR100814214B1/en
Application granted granted Critical
Publication of KR100814214B1 publication Critical patent/KR100814214B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A composition comprising an extract of Phyllostachys sap is provided to increase the activity of macrophages and natural killing cells directly facing tumor cells and promote the production of antibody against an external including tumor by increasing mitosis materials and physiologically active materials. An immuno-stimulating composition comprises an extract of Phyllostachys sap as an effective ingredient, wherein the extract is lyophilisate of the Phyllostachys sap. The composition is in the form of a food, a food additive or a pharmaceutical composition.

Description

대나무수액의 추출물을 유효성분으로 함유하는 면역증강용 조성물{IMMUNO-STIMULATIVE COMPOSITE COMPRISING EXTRACT FROM BAMBOO SAP}Immunity-enhancing composition containing extract of bamboo sap as active ingredient {IMMUNO-STIMULATIVE COMPOSITE COMPRISING EXTRACT FROM BAMBOO SAP}

도1은 대나무 수액의 추출물에 의한 림프구 증식 활성을 나타내는 그래프,1 is a graph showing the lymphocyte proliferation activity by the extract of bamboo sap,

도2는 대나무 수액 추출물의 싸이토카인 IL-2의 유도능력을 나타내는 그래프,Figure 2 is a graph showing the induction capacity of cytokine IL-2 of bamboo sap extract,

도3은 대나무 수액 추출물의 싸이토카인 IL-4의 유도능력을 나타내는 그래프,Figure 3 is a graph showing the induction capacity of cytokine IL-4 of bamboo sap extract,

도4는 대나무 수액 추출물의 싸이토카인 INF-r의 유도능력을 나타내는 그래프,Figure 4 is a graph showing the induction capacity of the cytokine INF-r of bamboo sap extract,

도5는 대나무 수액 추출물의 대식세포의 유도성 일산화 질소 신타아제의 유도능력(iNOS)을 나타내는 그래프,5 is a graph showing the induction capacity (iNOS) of inducible nitric oxide synthase of macrophages of bamboo sap extract,

도6은 대나무 수액 추출물의 대식세포의 증식을 유도하는 것을 나타내는 그래프이다.6 is a graph showing the induction of the proliferation of macrophages of bamboo sap extract.

본 발명은 대나무 수액의 추출물을 유효성분으로 함유하는 면역증강용 조성 물에 관한 것으로, 보다 상세하게는 상기 대나무 수액의 동결 건조물을 유효성분으로 함유하는 면역증강용 조성물과, 이를 함유하는 기능성 건강식품 또는 식품첨가제 및 약제조성물에 관한 것이다.The present invention relates to an immune enhancing composition containing an extract of bamboo sap as an active ingredient, and more particularly, an immune enhancing composition containing the freeze-dried product of the bamboo sap as an active ingredient, and a functional health food containing the same. Or it relates to food additives and pharmaceutical compositions.

대나무(Phyllostachys)는 화본과(Gramnineae)식물로서, 전 세계에 1,250여종이 있는 것으로 알려져 있고, 우리나라에서는 오래전부터 대나무가 많이 재배되어 왔는데 자생하고 있는 대나무의 종류는 13종이며, 대부분 전라남북도와 경남북도의 지역에 분포되어 있고, 강원도와 충청남도의 해안지방 그리고 제주도에 일부 분포하고 있다. Bamboo (Phyllostachys) is a plant native to Gramineae, and it is known that there are more than 1,250 species in the world. In Korea, bamboo has been cultivated for a long time. There are 13 kinds of bamboo grown in Korea. It is distributed in the area of, and is partly distributed in coastal areas of Gangwon-do and Chungcheongnam-do and Jeju-do.

예로부터 대나무는 고혈압, 발한, 중풍 등의 치료를 위한 민간약으로 활용이 되어 왔으며 방부 작용으로 하는 것으로도 알려져 있고, 그 수액보다는 줄기, 표피, 죽순 및 죽실 등이 질병 치료제로 이용되어져 왔으나 최근에는 고로쇠나무와 같이 수액을 채취하여 음용하고 있다. Since ancient times, bamboo has been used as a folk medicine for the treatment of hypertension, sweating, stroke, etc. It is also known as an antiseptic effect, and stem, epidermis, bamboo shoots and bamboo thread have been used as a medicine for treating diseases, but recently, Like sap, sap is collected and drinking.

이러한 대나무에 대한 연구중 대나무잎의 항미생물 활성에 대한 연구가 많이진행되어 있으나 대나무 수액에 대한 연구는 수액의 채취량과 채취 방법, 약수로의 이용 가능성에 대한 연구 정도만 행해지고 있다.While many studies have been conducted on the antimicrobial activity of bamboo leaves, research on bamboo sap has only been conducted on the sampling amount, the sampling method, and the availability of the distilled water.

수액이란 도관이나 사부를 통해 유동하는 액체로서 무기염, 질소화합물, 탄수화물, 효소, 식물호르몬 등이 용해되어 있는 비교적 묽은 용액이며, 수액의 조성은 물이 99.3%, 고형분은 0.7%에 불과하지만 보통의 물과는 엄청나게 다른 ‘물의 차별화’를 나타내고 있다. A sap is a liquid that flows through conduits or dead ends and is a relatively dilute solution in which inorganic salts, nitrogen compounds, carbohydrates, enzymes, and plant hormones are dissolved. The sap is composed of 99.3% water and 0.7% solids, but usually 'Water differentiation' is very different from water.

식물의 수액을 건강음료로 마시는 풍습은 소련, 중국, 일본에서는 오랜 역사 를 가지고 있으며 민간약으로 이뇨, 변비, 위장병, 고혈압, 혈당조절, 신경통 등에 효험이 있다고 하여 이들 수액의 성분에 관심이 높다. 수액을 산업화한 나라들의 경우 캐나다와 미국에서는 당단풍나무 수액을 가공하여 설탕 또는 시럽을 제조하며 일본 북해도에서는 자작나무 수액을 채취하여 건강음료로 판매하고 있다.The custom of drinking plant sap as a healthy drink has a long history in the Soviet Union, China, and Japan. It is a folk medicine that is effective in diuresis, constipation, gastrointestinal diseases, high blood pressure, blood sugar control, neuralgia, etc. In industrialized countries, sap maple syrup is processed in Canada and the United States to produce sugar or syrup, and birch sap is collected and sold as healthy drinks in Hokkaido, Japan.

대나무 수액은 고로쇠나무나 자작나무에 비해 더 많은 양의 수액을 채취할 수 있으며 당분과 무기성분의 함량이 특히 많아 전위, 이뇨, 신경 안정 및 심장질환의 발생 억제, 노폐물 제거 등에 효능이 있는 것으로 알려져 있으며, 타종에서 채취되는 수액과 비교하여 당과 무기성분의 함량이 높아 음용수로서의 가치가 높으으면서 항미생물의 활성이 큰 것으로 나타나 천연항균 물질로서의 이용 가능성도 보인다.Bamboo sap can collect more sap than cypress and birch, and it is known to be effective in dislocation, diuresis, nerve stabilization and suppression of heart disease, and elimination of waste products due to its high content of sugar and inorganic components. In addition, compared to the sap collected from other species, the content of sugar and inorganic components is high, the value of drinking water is high, and antimicrobial activity is shown to be great, so it can be used as a natural antibacterial substance.

우리나라에서는 지금까지 주로 대나무 자체의 가공기술, 즉 죽세공예기술의 개발에 대한 연구가 어느 정도 수행된 바 있으나 대나무 자원의 약리 효능이나 기능성을 이용한 기술개발은 거의 없었고 최근에 일부 학자들에 의해 대나무 추출액에 대한 항미생물의 활성에 관한 연구가 진행되고 있는 수준이다.In Korea, some studies have been conducted on the development of bamboo processing technology, that is, bamboo arts and crafts technology. Until now, however, there has been little development of technology using pharmacological efficacy or functionality of bamboo resources. The research on the activity of antimicrobial activity against is ongoing.

그리고, 국외에서의 대나무 자원에 대한 연구는 중국과 일본에서 일부 수행된 바 있고, 특히 중국의 경우 대나무 자원을 다양하게 이용해오고 있으나 주로 대나무를 이용한 건축자재 등의 산업화에 주력하고 있으며 대나무를 기능성 식품소재로 이용하는 기술은 아직까지 초보적인 단계에 있으며, 현재로서는 ‘죽건’이라는 대나무 음료를 개발하여 유통시키고 있는 실정이고 죽엽 추출물을 조제하여 쌀에 코팅한 ‘죽향미’도 개발된 바 있다.In addition, some research on bamboo resources in foreign countries has been conducted in China and Japan. Especially, in China, bamboo resources have been used in various ways, but mainly focus on industrialization of building materials using bamboo, and bamboo is a functional food. The technology used as a material is still in its infancy, and at present it is a state of developing and distributing bamboo beverages called 'jukgun' and 'juk flavor' coated with rice by preparing bamboo leaf extract has also been developed.

이처럼, 고로쇠수액, 단풍나무수액, 자작나무수액 등은 약리효과에 대한 여러 가지 연구가 진행된 바 있으나, 대나무 수액에 대한 연구는 많이 되어 있지 않고 특히, 그 약리효과에 대해서는 아직 보고된 바가 없다.As such, gorgo sap, maple sap, birch sap, etc. have been studied variously on the pharmacological effect, but the research on the bamboo sap has not been much, especially the pharmacological effect has not been reported yet.

본 발명은 대나무 수액의 동결 건조물을 유효성분으로 포함하는 면역증강용 조성물과 이를 함유한 기능성 건강식품 또는 식품첨가제 및 약제조성물을 제공하는 데에 그 목적이 있다.An object of the present invention is to provide a composition for immuno-enhancement comprising a freeze-dried product of bamboo sap as an active ingredient, and a functional health food or food additive and pharmaceutical composition containing the same.

상기한 목적을 달성하기 위하여 본 발명은 대나무 수액의 동결건조물을 함유한 실험군과 상기 추출물을 함유하지 않은 대조군으로 유사분열물질의 활성, 생리활성물질의 유도능, 생체내 급성독성시험, 유도성 일산화질소 신타아제 유전자 발현 및 NO 생성능, 자연살해세포 활성화 정도에 따른 면역증강 작용을 입증하여 대나무 수액의 동결건조물을 유효성분으로 하는 면역증강용 조성물과, 이를 함유한 기능성 건강식품 또는 식품첨가제 및 약제조성물을 제공하게 된다.In order to achieve the above object, the present invention is the experimental group containing the lyophilized bamboo sap and the control group does not contain the extract activity of the mitotic substance, the inducibility of the bioactive substance, in vivo acute toxicity test, inducible monoxide Immune synthetase gene expression, NO production ability, and natural immune cell activation, and proved the immune enhancing effect of the lyophilized composition of bamboo sap as an active ingredient, functional health food or food additives and pharmaceutical compositions containing the same Will be provided.

이하에서는 첨부된 도면을 참조하여 본 발명의 바람직한 실시예를 상세히 설명하기로 한다.Hereinafter, with reference to the accompanying drawings will be described a preferred embodiment of the present invention;

도1은 대나무 수액의 추출물에 의한 림프구 증식 활성을 나타내는 그래프이고, 도2는 대나무 수액 추출물의 싸이토카인 IL-2의 유도능력을 나타내는 그래프이며, 도3은 대나무 수액 추출물의 싸이토카인 IL-4의 유도능력을 나타내는 그래프이고, 도4는 대나무 수액 추출물의 싸이토카인 INF-r의 유도능력을 나타내는 그래프 이며, 도5는 대나무 수액 추출물의 대식세포의 유도성 일산화 질소 신타아제의 유도능력(iNOS)을 나타내는 그래프이고, 도6은 대나무 수액 추출물의 대식세포의 증식을 유도하는 것을 나타내는 그래프이다.1 is a graph showing the lymphocyte proliferation activity by the extract of the bamboo sap, Figure 2 is a graph showing the induction ability of the cytokine IL-2 of bamboo sap extract, Figure 3 is the induction capacity of the cytokine IL-4 of bamboo sap extract 4 is a graph showing the induction capacity of the cytokine INF-r of the bamboo sap extract, Figure 5 is a graph showing the induction capacity (iNOS) of the induced nitric oxide synthase of macrophages of the bamboo sap extract , Figure 6 is a graph showing inducing the proliferation of macrophages of bamboo sap extract.

실시예 1; 대나무 수액의 동결건조분말 제조Example 1; Lyophilized Powder Preparation of Bamboo Sap

본 발명의 재료인 대나무 수액의 채취는 5~6월에 채취하였으며, 채취한 대나무 수액은 동결 건조를 통해 분말화한 후 -20℃의 온도에서 사용 전까지 보관하였고, 동물세포에 처리 전 500mg/ml의 농도로 녹여, 망크기(pore size)가 0.22㎛인 멤브레인 필터(membrane filter)로 여과시켜 -20℃에 보관하고 실험에 이용하였다.The harvesting of bamboo sap, the material of the present invention, was collected in May-June, and the collected bamboo sap was powdered by freeze-drying and stored at -20 ° C until use, and 500 mg / ml before treatment in animal cells. It was dissolved at a concentration of and filtered through a membrane filter (pore size) of 0.22㎛ (membrane filter) and stored at -20 ℃ was used for the experiment.

비교예 1; 대나무 수액이 면역관련세포의 유사분열물질(mitogen)에 미치는 영향Comparative Example 1; Effect of Bamboo Sap on Mitogen in Immune-Related Cells

5주령의 Balb/c 마우스로부터 비장을 적출하고, 비장세포(splenocytes)의 수가 2×105 /100㎕의 밀도로 조정하여 각 웰(well)에 넣고 대나무 수액을 각각 200㎍/㎖, 100㎍/㎖, 50㎍/㎖ 및 10㎍/㎖를 첨가하였다.Harvesting the spleen from the Balb / c mice of 5 weeks of age, and the number of spleen cells (splenocytes) adjusted to a density of 2 × 10 5 / 100㎕ to put into each well (well) to each bamboo sap 200㎍ / ㎖, 100㎍ / Ml, 50 μg / ml and 10 μg / ml were added.

양성 대조군으로 T-세포 및 B-세포의 유사분열 물질인 콘카바날린-A(Concavanallin-A;이하 Con-A라 약칭함)와 지질 다당류(Lipopolysaccharide;이하 LPS라 약칭함)의 최종농도가 각각 0.5㎍/㎖ 및 5㎍/㎖가 되도록 조정하여 각 웰(well)에 처리하고, 실험군과 대조군을 37℃, 5% CO2 조건 하에서 3일간 배양하고 시료에 의한 림프구의 증식활성(proliferation assay)을 조사하였다.As a positive control, the final concentrations of concavanallin-A (hereinafter referred to as Con-A) and lipopolysaccharide (hereinafter referred to as LPS), which are mitotic substances of T-cell and B-cell, respectively Each well was adjusted to 0.5 μg / ml and 5 μg / ml, and the experimental and control groups were incubated for 3 days at 37 ° C. and 5% CO 2, and the proliferation assay of the lymphocytes by the sample was observed. Was investigated.

림프구(Lymphocyte)의 증식활성(proliferation activity)은 MTT[3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]법으로 수행하였으며, 상기 MTT법은 5㎎/㎖의 농도로 조정된 MTT시약을 각 웰(well)에 50㎕첨가하고 6시간 배양하여 MTT시약과 살아있는 세포가 생산하는 미토콘드리아 탈수소효소(mitochondria dehydrogense)와 반응하여 생성된 비수용성의 진청색 포마잔(formazan)의 양을 570㎚에서 흡광도를 측정함으로써 림프구의 증식활성을 측정하였다. Lymphocyte proliferation activity was performed by MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide] method, and the MTT method was 5 mg / ml. 50 μl of the concentration-adjusted MTT reagent was added to each well and incubated for 6 hours to react with the mitochondria dehydrogense produced by the MTT reagent and living cells, resulting in non-aqueous dark blue formazan. The proliferative activity of lymphocytes was measured by measuring the absorbance at 570 nm.

본 비교예 1의 결과는 도 1에 나타낸 바와 같이 대나무 수액 동결 건조물이 시료 무처리 대조군에 비하여 높은 비장세포의 증식활성을 나타내었다.As shown in FIG. 1, the result of Comparative Example 1 showed that the sap freeze-dried product showed higher proliferation activity of splenocytes compared to the sample-free control group.

본 비교예의 결과로서 본 발명이 B-세포 또는 T-세포 중 어떤 종류의 면역세포를 활성화시키는지 확인하지 못하였으나 비특이적으로 비장세포를 직접 자극하는 활성작용이 있음을 확인하였다. As a result of this comparative example, it was not confirmed whether the present invention activates any kind of immune cells among B-cells or T-cells, but it was confirmed that there is an activating activity that directly stimulates splenocytes nonspecifically.

또한, 유사한 실험으로 5주령의 Balb/c 3% 티오글리콜레이트(thioglycollate) 1㎖를 복강투여하고 3일 후에 마우스의 복강세포(Perotoneal Exaudative Cell; 이하 PEC라 약칭함)를 멸균적으로 수집하여 24웰 플레이트(48well plate)의 각 웰(well)에 1×106/㎖의 농도로 도말한 후, 2시간 정도 배양하고 PBS로 각 웰(well)을 세척하여 플레이트에 부착된 대식세포(macrophage)를 회수하였다. In a similar experiment, 1 ml of 5 weeks old Balb / c 3% thioglycollate was intraperitoneally administered and 3 days later, sterile cells of mice were sterilely collected (24). Each well of the well plate (48 well plate) is plated at a concentration of 1 × 10 6 / ㎖, incubated for about 2 hours and washed each well with PBS (macrophage attached to the plate) Was recovered.

INF-r와 동시에 대나무 수액을 각각 200㎍/㎖, 100㎍/㎖, 50㎍/㎖ 및 10㎍/㎖ 로 처리하여 iNOS 및 NO의 생성량을 정량하였다. The amount of iNOS and NO was quantified by treating bamboo sap with INF-r at 200 µg / ml, 100 µg / ml, 50 µg / ml and 10 µg / ml respectively.

실험 수행 결과 대나무 수액 단독 처리군에서는 NO 및 iNOS의 생성 변화를 관찰할 수 없었으나, INF-r와 동시 처리한 군에서는 시료의 농도에 의존하여 NO 및 iNOS의 값이 증가하는 것을 관찰할 수 있었다. As a result of the experiment, NO and iNOS production change could not be observed in the bamboo sap treatment group, but the increase of NO and iNOS value was observed in the group treated with INF-r depending on the concentration of the sample. .

본 비교예의 결과로 본 발명은 성숙된 면역담당세포가 효과적인 면역반응을 유도케 하는 세포반응성을 증진시키는 효과가 있으며, 외부의 항원에 노출되었을 경우 본 발명이 투여된 생체는 비특이적 면역 반응 뿐만 아니라, 항원 특이적인 면역반응을 위한 작동세포의 수를 증가시키므로 외부로부터의 항원에 대하여 효과적인 방어효과를 유도할 수 있는 것으로 확인하였다.As a result of this comparative example, the present invention has the effect of enhancing the cellular reactivity of the mature immune cells to induce an effective immune response, when exposed to an external antigen, the living body to which the present invention is administered is not only a nonspecific immune response, Since the number of effector cells for the antigen-specific immune response is increased, it was confirmed that it can induce an effective protective effect against the antigen from the outside.

비교예 2Comparative Example 2

1. 대나무 수액의 생리활성물질(cytokine)의 유도 1. Induction of Cytokine from Bamboo Sap

대나무 수액이 면역관련세포의 유사분열물질(mitogen)에 미치는 영향Effect of Bamboo Sap on Mitogen in Immune-Related Cells

5주령의 Balb/c 마우스로부터 비장을 적출하고, 비장세포(splenocytes)의 수를 2×106 /500㎕의 밀도로 조정하여 각 웰(well)에 넣고 대나무 수액을 각각 200㎍/㎖, 100㎍/㎖, 50㎍/㎖ 및 10㎍/㎖를 첨가하여 24시간 동안 동시배양 하였다.Harvesting the spleen from the Balb / c mice of 5 weeks of age, and by adjusting the number of spleen cells (splenocytes) at a density of 2 × 10 6 / 500㎕ put into each well (well) to each bamboo sap 200㎍ / ㎖, 100 Co-culture was performed for 24 hours by the addition of μg / ml, 50 μg / ml and 10 μg / ml.

또한, 양성 대조군으로 Con A의 최종농도를 0.5㎍/㎖가 되도록 조정하여 웰(well)에 처리하고 24시간 동안 배양하였고, 배양완료 후에 상등액만을 회수하고 상등액에 유도 분비된 IL-2, IL-4, IL-10, INF-r 등 여러 가지 생리활성물질(cytokine)을 각 싸이토카인 킷(cytokine kit)을 이용하여 측정하였다.In addition, the final concentration of Con A was adjusted to be 0.5 μg / ml as a positive control, treated in wells and incubated for 24 hours. After the incubation, only the supernatant was recovered and the secreted induction into the supernatant was IL-2 and IL-. Various cytokines such as 4, IL-10, INF-r, etc. were measured using each cytokine kit.

본 비교예 2의 결과는 도 2 내지 도 4에 나타낸 바와 같이 대나무 수액은 마 우스의 췌장 세포를 직접 활성화시켜 IL-2, IL-4, IL-10, INF-r 등의 면역 관련 싸이토카인을 유도하는 면역자극효과가 있음을 확인하였다.As shown in FIGS. 2 to 4, bamboo sap directly activates mouse pancreatic cells to induce immune-related cytokines such as IL-2, IL-4, IL-10, and INF-r. It was confirmed that the immune stimulating effect.

본 발명은 싸이토카인의 종류, 대나무 수액의 농도에 따라 싸이토카인을 유도하는 정도가 달랐으나, 농도에 의존하여 싸이토카인 유도체(cytokine inducer)로의 활성이 있음을 확인하였다.In the present invention, the degree of inducing cytokine was different depending on the type of cytokine and the concentration of the sap of bamboo, but it was confirmed that there is activity as a cytokine derivative (cytokine inducer) depending on the concentration.

2. 대나무 수액의 생체내 급성독성 시험2. In vivo acute toxicity test of bamboo sap

25g의 웅성 Balb/c 마우스에 대나무 수액을 구강 투여를 통해 마우스당 2,000㎍/kg, 500㎍/kg 및 100㎍/kg을 2일 간격으로 계속 투여 하였으며, 15일간 마우스의 생존율 및 체중을 조사하였다.25 g of male Balb / c mice were orally administered with 2,000 sag / kg, 500 μg / kg and 100 μg / kg per mouse via oral administration, and the survival and body weight of the mice were examined for 15 days. .

본 비교예에 의한 대나무 수액을 투여한 마우스의 생존율 및 체중 그리고 간 수치를 각각 다음의 표 1 내지 표 3에 나타내었다.Survival, body weight and liver values of the mice administered bamboo sap according to the comparative example are shown in Tables 1 to 3, respectively.

표 1. 대나무수액을 투여한 마우스의 생존율Table 1. Survival rate of mice administered bamboo sap

투여방법Dosing method 투여용량Dosage 투여일/생존율(%)Dosing date / survival rate (%) 생존율 (%)Survival rate (%) 1일1 day 3일3 days 5일5 days 7일7 days 9일9th 12일12 days 15일15th 구강투여Oral administration 2mg/kg2mg / kg 100100 100100 100100 100100 100100 100100 100100 100100 0.5mg/kg0.5mg / kg 100100 100100 100100 100100 100100 100100 100100 100100 100㎍/kg100 µg / kg 100100 100100 100100 100100 100100 100100 100100 100100

표 2. 대나무수액을 투여한 마우스의 체중변화Table 2. Changes in body weight of mice administered bamboo sap

투여방법Dosing method 투여용량Dosage 투여일/생존율(%)Dosing date / survival rate (%) 체중변화 (%)Weight change (%) 1일1 day 3일3 days 5일5 days 7일7 days 9일9th 12일12 days 15일15th 구강투여Oral administration controlcontrol 20.3±0.220.3 ± 0.2 20.7±0.420.7 ± 0.4 21.3±0.521.3 ± 0.5 21.5±0.721.5 ± 0.7 22.1±0.622.1 ± 0.6 21.9±0.521.9 ± 0.5 22.3±0.522.3 ± 0.5 109.8109.8 2mg/kg2mg / kg 20.1±0.320.1 ± 0.3 20.4±0.520.4 ± 0.5 20.9±0.420.9 ± 0.4 21.1±0.621.1 ± 0.6 21.7±0.821.7 ± 0.8 22.1±0.622.1 ± 0.6 21.9±0.421.9 ± 0.4 108.9108.9 0.5mg/kg0.5mg / kg 20.1±0.320.1 ± 0.3 21.0±0.221.0 ± 0.2 21.5±0.621.5 ± 0.6 21.3±0.921.3 ± 0.9 22.3±0.422.3 ± 0.4 22.8±0.822.8 ± 0.8 22.9±0.622.9 ± 0.6 113.9113.9 100㎍/kg100 µg / kg 19.9±0.419.9 ± 0.4 20.3±0.620.3 ± 0.6 21.7±0.221.7 ± 0.2 21.4±0.721.4 ± 0.7 21.2±0.821.2 ± 0.8 21.7±0.421.7 ± 0.4 22.4±0.622.4 ± 0.6 112.5112.5

표 3. 대나무 수액을 투여한 마우스의 간수치Table 3. Liver Numbers of Mice Administered with Bamboo Sap

DoseDose No. fo mouseNo. fo mouse ALT(unit/ml)ALT (unit / ml) AST(unit/ml)AST (unit / ml) MortalityMortality controlcontrol 1010 8.8± 0.28.8 ± 0.2 19.5± 0.419.5 ± 0.4 00 2mg/kg2mg / kg 1010 8.7± 0.58.7 ± 0.5 18.9± 0.618.9 ± 0.6 00 0.5mg/kg0.5mg / kg 1010 8.9± 0.18.9 ± 0.1 19.3± 0.219.3 ± 0.2 00 100㎍/kg100 µg / kg 1010 8.6± 0.48.6 ± 0.4 18.8± 0.318.8 ± 0.3 00

상기 표 1에 나타낸 바와 같이 대나무 수액은 투여량에 관계없이 마우스의 생존율에 영향을 미치지 않는 것으로 나타났으며, 이와 같은 결과는 상기 대나무 수액이 생체의 생존에 영향을 미치지 않음을 증명하였다.As shown in Table 1, the bamboo sap did not appear to affect the survival rate of the mice regardless of the dose, this result proved that the bamboo sap does not affect the survival of the living body.

또한, 상기 표 2에 나타낸 바와 같이 대나무 수액을 처리한 실험군은 시료 무처리 대조군과 유사한 체중증가를 나타냄으로써 대나무 수액은 생체의 조직적 손상을 유도하지 않는 결과를 나타내었다.In addition, as shown in Table 2, the experimental group treated with the bamboo sap showed a similar weight gain as the sample untreated control group, indicating that the bamboo sap did not induce tissue damage of the living body.

그리고, 상기 표 3에서 보는 바와 같이 대나무 수액 처리군의 간수치를 조사한 결과 정상군과 유의성 있는 차이를 보이지 않아 아무런 간손상도 유발하지 않은 것을 관찰할 수 있었다.And, as shown in Table 3 above, as a result of examining the liver digits of the bamboo sap treatment group did not show a significant difference with the normal group, it could be observed that did not cause any liver damage.

3. 자연살해세포(Natural Killer cell; 이하 NK-세포라 약칭함)활성화에 미치는 효과 측정3. Determination of the effect on the activation of natural killer cells (abbreviated as NK-cells)

22g의 웅성 Balb/c 마우스에 대나무 수액을 각각 200㎍/kg, 50㎍/kg 및 10㎍/kg을 7일 동안 구강 투여하고 7일 후 마우스의 비장을 멸균적으로 수획한 비장세포와 NK-세포에 민감세포주인 YAC-1을 동시에 6시간 배양하였다. 22 g of male Balb / c mice were orally administered 200 μg / kg, 50 μg / kg and 10 μg / kg of bamboo sap respectively for 7 days, and after 7 days the spleen cells and NK- The cells were incubated for 6 hours with YAC-1, a sensitive cell line.

배양한 비장세포를 효과 기주세포(Effector cell; E)로 사용하고, 배양한 YAC-1을 표적세포(Target cell;T)로 사용하였다. Cultured splenocytes were used as effector cells (E) and cultured YAC-1 was used as target cells (T).

NK-세포에 의한 살해효과는 자연살해세포의 세포독성 분석법인 크롬-유리법( 51 Cr-release법)을 이용하여 상기 표적세포와 효과기세포를 1,400rpm으로 1분간 원심분리하고 37℃에서 4시간 배양하였다. The killing effect by NK-cells was centrifuged at 1,400 rpm for 1 minute using chromium-free method (51 Cr-release method), which is a cytotoxicity assay of natural killer cells, and 4 hours at 37 ° C. Incubated.

스카트론(Skatron)기기를 사용하여 상층액을 회수하고 g-계수기로 계수하고 세포독성 프로그램으로 실험적 유리량(experimental release), 자연적 유리량(spont aneous release), 최대 유리량(maximum release)을 측정하여 이하의 식으로 NK-세포의 활성을 산출하였다. Supernatant was recovered using a Skatron instrument, counted with a g-counter, and cytotoxic programs measured for experimental release, spontaneous release, and maximum release. In this way, the activity of NK-cells was calculated.

NK-세포의 활성(%)=[실험적 유리량(experimental release)-자연적 유리량(spontaneous release)/최대 유리량(maximum release)-자연적 유리량(spontaneous release)]×100NK-cell activity (%) = [experimental release-spontaneous release / maximum release-spontaneous release] × 100

표 4. 대나무수액이 자연살해 세포에 미치는 영향Table 4. Effect of Bamboo Sap on Natural Killing Cells

투여방법Dosing method 투여용량Dosage E/T 비율E / T ratio 100100 5050 2525 구강투여Oral administration controlcontrol 13.2 ± 4.813.2 ± 4.8 9.3 ± 7.49.3 ± 7.4 7.3 ± 7.97.3 ± 7.9 200㎍/kg200 µg / kg 48.5 ± 8.348.5 ± 8.3 34.3 ± 4.834.3 ± 4.8 23.3 ± 4.623.3 ± 4.6 50㎍/kg50 µg / kg 29.7 ± 2.529.7 ± 2.5 24.3 ± 5.224.3 ± 5.2 21.3 ± 4.821.3 ± 4.8 10㎍/kg10 µg / kg 18.9 ± 7.418.9 ± 7.4 17.3 ± 7.317.3 ± 7.3 16.3 ± 9.316.3 ± 9.3

상기 표 4에 나타낸 바와 같이 대나무 수액이 미치는 NK-세포 활성은 E/T 비율과 대나무 수액에 비례함을 확인하였다.As shown in Table 4, it was confirmed that the NK-cell activity of bamboo sap is proportional to the E / T ratio and bamboo sap.

대나무 수액을 투여한 실험군과 대조군을 비교하였을 때 대나무 수액 200㎍을 투여한 마우스의 비장세포는 대조군 마우스에 비하여 약 4배 정도의 NK-세포 활성을 나타내었으며 대나무 수액 10㎍을 투여한 경우도 대조군에 비하여 유효한 활성을 나타냈다.Compared with the control group administered with bamboo sap and the control group, the splenocytes of mice treated with 200 μg of bamboo sap showed about four-fold NK-cell activity compared to the control mice. Compared to the effective activity was shown.

상기와 같이 대나무 수액으로 인한 림프구 증식활성, 생리활성물질의 유도능력, 생체내 독성시험, iNOS 및 NO의 유도능력 , 자연살해세포 활성화 등에 유리하게 작용함을 입증하였다.As described above, it was proved to be beneficial for lymphocyte proliferation activity due to the sap of bamboo, the ability to induce physiologically active substances, in vivo toxicity test, the ability to induce iNOS and NO, activation of natural killer cells.

상기 대나무 수액을 식품 또는 약제의 조성물로 사용할 수 있으며 상기 추출물을 동결건조 또는 농축액의 형태로 식품 또는 약제의 조성물로 사용할 수 있다.The bamboo sap may be used as a composition of food or medicament, and the extract may be used as a composition of food or medicament in the form of lyophilization or concentrate.

하기에서 상기 조성물의 제제예를 구체적으로 설명하기로 한다.Hereinafter, the preparation examples of the composition will be described in detail.

제제예; 건강기능성음료의 제조Formulation examples; Preparation of Health Functional Drink

실시예; 대나무수액 1~15중량%Example; Bamboo sap 1-15% by weight

대나무수액의 농축액 1~2중량%           1 ~ 2% by weight of bamboo sap

액상과당 1~10중량%           1 to 10 wt% of liquid fructose

구연산 0.01~1중량%           Citric acid 0.01 ~ 1% by weight

대나무추출액 0.05~0.5중량%           Bamboo extract 0.05 ~ 0.5% by weight

베타인 0.01~1.0중량%           Betaine 0.01 ~ 1.0 wt%

식이섬유 0.1~1.0중량%           Dietary Fiber 0.1 ~ 1.0% by weight

과즙농축액 0.1~2.0 중량%           Juice concentrate 0.1 ~ 2.0 wt%

정제수를 가하여 전체 800ml           Add 800 ml of purified water

예컨대, 본 발명의 대나무 수액의 추출물을 이용한 건강기능성음료는 통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 80℃에서 30분정도 살균한 후 용기에 넣어 밀봉하여 2차 저온살균시킨 후 유리병 등 소포장용기에 포장하여 건강기능성음료를 제조하였다.For example, the health functional beverage using the extract of the bamboo sap of the present invention is mixed with the above components according to the conventional health beverage manufacturing method, sterilized for about 30 minutes at 80 ℃ and sealed in a container to secondary pasteurization After packaging in a small packaging container such as glass bottles to prepare a health functional beverage.

이와 같이, 본 발명의 상세한 설명에서는 구체적인 실시예에 관해 설명하였으나, 이는 본 발명의 범주에서 벗어나지 않는 한도내에서 여러가지 변형이 가능함은 물론이다.As described above, in the detailed description of the present invention, specific embodiments have been described, but various modifications may be made without departing from the scope of the present invention.

그러므로, 본 발명의 실질적인 범위는 상술된 실시예에 의해 한정되어져서는 안되며, 후술하는 청구범위 뿐만 아니라 청구범위와 균등한 구성에 의해 정해져야 함은 당연하다.Therefore, the substantial scope of the present invention should not be limited by the above-described embodiment, but should be defined by the same structure as the claims as well as the claims described below.

이상과 같이 구성되는 본 발명은 대나무 수액을 유효성분으로 하는 면역증강용 조성물을 추출함으로써 상기 면역증강용 조성물의 투여는 종양세포에 대해 직접적으로 대항하는 대식세포 및 자연살해세포의 활성을 높이고, 유사분열 물질 및 생리활성물질을 증가시켜 종양을 비롯한 외부 항원에 대한 항체 생산을 증진시키는 효과가 있다.The present invention is configured as described above by extracting the composition for immuno-enhancing bamboo sap as an active ingredient, the administration of the immuno-enhancing composition increases the activity of macrophages and natural killer cells directly against tumor cells, and similar Increasing cleavage and bioactive substances has the effect of enhancing the production of antibodies to foreign antigens, including tumors.

또한, 본 발명은 상기 대나무 수액을 식품 또는 식품첨가제 및 약제에 조성물로 사용함으로써 일상의 식생활로 면역과 관련된 질환을 예방하는 효과가 있다.In addition, the present invention has the effect of preventing diseases associated with immunity to daily diet by using the bamboo sap as a composition in food or food additives and pharmaceuticals.

Claims (5)

대나무 수액에서 추출한 추출물을 유효성분으로 하는 면역증강용 조성물.Immunity-enhancing composition comprising the extract extracted from the sap of bamboo as an active ingredient. 청구항 1에 있어서,The method according to claim 1, 상기 추출물은 대나무 수액의 동결건조물인 것을 특징으로 하는 면역증강용 조성물.The extract is an immune enhancing composition, characterized in that the lyophilized bamboo sap. 청구항 1에 있어서,The method according to claim 1, 상기 조성물은 식품으로 제공되는 것을 특징으로 하는 면역증강용 조성물.The composition is an immune enhancing composition, characterized in that provided as a food. 청구항 1에 있어서,The method according to claim 1, 상기 조성물은 식품첨가제로 제공되는 것을 특징으로 하는 면역증강용 조성물.The composition is an immune enhancing composition, characterized in that provided as a food additive. 청구항 1에 있어서,The method according to claim 1, 상기 조성물은 약제조성물로 제공되는 것을 특징으로 하는 면역증강용 조성물.The composition is an immune enhancing composition, characterized in that provided as a pharmaceutical composition.
KR1020060098710A 2006-10-11 2006-10-11 Immuno-stimulative composite comprising extract from bamboo sap KR100814214B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020060098710A KR100814214B1 (en) 2006-10-11 2006-10-11 Immuno-stimulative composite comprising extract from bamboo sap

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060098710A KR100814214B1 (en) 2006-10-11 2006-10-11 Immuno-stimulative composite comprising extract from bamboo sap

Publications (1)

Publication Number Publication Date
KR100814214B1 true KR100814214B1 (en) 2008-03-17

Family

ID=39410731

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020060098710A KR100814214B1 (en) 2006-10-11 2006-10-11 Immuno-stimulative composite comprising extract from bamboo sap

Country Status (1)

Country Link
KR (1) KR100814214B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102657275B1 (en) * 2023-11-03 2024-04-15 주식회사 비오맘 Food composition for improving diet and bowel movement with improved intake and absorption power

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006022739A (en) * 2004-07-08 2006-01-26 Toyota Motor Corp Exhaust emission control system for internal combustion engine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006022739A (en) * 2004-07-08 2006-01-26 Toyota Motor Corp Exhaust emission control system for internal combustion engine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
대한한방내과학회지 18(2), 27-39 (1997)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102657275B1 (en) * 2023-11-03 2024-04-15 주식회사 비오맘 Food composition for improving diet and bowel movement with improved intake and absorption power

Similar Documents

Publication Publication Date Title
KR102178926B1 (en) A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use
KR101734979B1 (en) Composition for preventing and treating cancer, and enhancing the immune action
KR101184349B1 (en) Composition for enhancement of immune function and improvement of hematopoiesis which comprises antler fermented with Bacillus subtilis KCTC 11454BP as an active ingredient, and a preparation method thereof
KR20180090198A (en) Composition comprising the extract of Molokia leaf for immune activity
KR101356611B1 (en) Vinegar of fermented pepper leaf with increased AGI activity and method for preparing the same
KR102315959B1 (en) A composition for reinforcing immune function comprising the extract of oat sprout
KR100814214B1 (en) Immuno-stimulative composite comprising extract from bamboo sap
KR101704123B1 (en) Method for seperating bee venom containing active amines and food composition thereof
KR102368892B1 (en) A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino
KR101626642B1 (en) Composition comprising fermented extract of trifoliate orange for improving diabetes
KR20210003994A (en) Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same
KR101604347B1 (en) Pharmaceutical composition comprising an extract or a fraction of Pistacia weinmannifolia J. Poiss. Ex Franch for preventing or treating inflammatory-related diseases
KR101113603B1 (en) Extract composition of herbal mixture for improving liver fucntion and relieving hangover
KR20200065170A (en) Composition for Prophylaxis and Treatment of Osteoporosis, Diabetes and Obesity Comprising Fermented Tremella fuciformis Berk.
KR102470155B1 (en) Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale
JP4327727B2 (en) Composition for the treatment and immunity enhancement of myeloid leukemia containing hamcho extract
KR20210147247A (en) A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture
KR100510174B1 (en) Composition for treating myeloid leukemia and increasing immunity comprising Salicornia herbacea extracts.
KR101488434B1 (en) Immune-enhancing composition including inonotus obliquus extract
KR101184355B1 (en) Composition for enhancement of immune function and improvement of hematopoiesis which comprises antler fermented with Cordyceps militaris KCTC 11455BP as an active ingredient, and a preparation method thereof
KR101715996B1 (en) Composition for antidiabetic activity comprising dichloromethane or ethyl acetate fraction of Hizikia fusiformis extract as effective component
KR102691084B1 (en) A composition for improving and preventing obesity comprising complex-fermented fruits of Cudrania tricuspidata and its preparation method
KR102093817B1 (en) Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same
KR102527252B1 (en) A composition for improving immune comprising enzyme hydrolysate containing Rhodiola sachalinensis A. Bor
KR100657423B1 (en) Pharmaceitical composition for immune improvement comprising protein extract, crude protein-polysaccharide extract of korean acanthopanax senticosus extract which were extracted korean acanthopanax senticosus

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20120409

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20121226

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20160318

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee